The invention provides a method of treating obesity, diabetes, and/or
cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood
pressure, and insulin resistance) in a mammal by administering to the
mammal a therapeutically effective amount of an irreversible MAO-B
inhibitor.